Clinical Transplantation · 2018 · 26 citations · 17 references
MedicineHematologyOncologyHematologic OncologyStem Cell TransplantationTransplant ImmunologyCancer Survival AnalysisMultiple MyelomaTransplant OutcomesAutologous Stem Cell TherapyKaplan-meier Survival EstimatesNeutrophil-to-lymphocyte RatioPlatelet-to-lymphocyte RatioPredictors Of SurvivalPrognostic BiomarkersPrognostic Marker EvaluationSurvival After Autologous Transplantation
BACKGROUND: Recent reports have showed that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are predictors of progression-free survival (PFS) and overall survival (OS) in many types of cancer. This study evaluates the predictive value of NLR, MLR, and PLR for survival in MM patients treated with to ASCT. METHODS: A set of data consisting of 150 patients who underwent autologous stem cell transplantation (ASCT) for MM was collected retrospectively. The prognostic value of NLR, MLR, and PLR was investigated with Kaplan-Meier method. RESULTS: The prognostic value of NLR, MLR, and PLR was analyzed by a receiver operating characteristic (ROC) curve established to determine the cutoff. These cutoff values of NLR, PLR, and MLR were found 1.46, 86, and 0.27, respectively, on the 100th day of post-transplantation period. The overall survival (OS) and the post-transplantation OS of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation were shorter than the other group (P = 0.05, P = 0.018 [NLR], P = 0.05, P = 0.002 [MLR], P = 0.000, P = 0.001 [PLR]). The post-transplantation progression-free survival (PFS) of the patients with high NLR, MLR, and PLR levels on the 100th day of post-transplantation was shorter as well (P = 0.036, P = 0.001, P = 0.001, respectively). CONCLUSION: As increased NLR, MLR, and PLR predicted poor clinical outcome in MM patients with autologous transplantation in this study, they may serve as cost-effective and rapidly available prognostic biomarkers for these patients.
17
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma
C. Scavelli, Beatrice Nico, Teresa Cirulli et al. · Oncogene · 2007 · 140 citations · Full text
Medicine, Hematology, Immunology +16
Optimization of the systemic inflammation‐based Glasgow Prognostic Score
Michael Proctor, Paul G. Horgan, Dinesh Talwar et al. · Cancer · 2013 · 108 citations